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The 19th Paterson symposium held at the Christie
Hospital and Holt Radium Institute, Manchester
on November 18-21, 1984 took as its title
"Haemopoietic Cell Growth Factors". The scope of
this subject has led to a multidisciplinary approach
being adopted in recent years with major
contributions in the field being made by protein
chemists, molecular biologists, cell biologists and
haematologists. All of these disciplines were repre-
sented in the meeting with contributing scientists
from Australia, Europe and USA as well as the UK.
All those participating are actively involved in the
search for, and characterization of, these regulatory
molecules and also in discerning their relative
roles in haemopoiesis in vivo and in leukaemic cell
proliferation.
Purification, characterization and receptor binding of
haemopoietic cellgrowthfactors
The essential starting points for an analysis of these
molecules and their respective roles in haemopoiesis
are their purification and characterization of
biological activity. Several groups reported the
isolation of specific haemopoietic growth factors
with differing lineage restrictions and target cell
population specificities. E. Goldwasser (University of
Chicago USA) described the chemistry of purified
erythropoietin, a key regulatory factor in
erythropoiesis. This molecule is a glycoprotein (mol.
wt34,000) containing 24-31% carbohydrate which
is essential for in vivo activity, but not in vitro
biological activity. There are three domains, two
protease resistant (containing all of the
carbohydrate) joined by a third connecting region
that contains the active region. This purified
molecule can rapidly induce the transcription of
globin mRNA in pure populations of late erythroid
progenitor cells (CFU-e). To study receptor binding
of erythropoietin Goldwasser used an erythro-
leukaemia cell line which produces haemoglobin in
response to erythropoietin. He established that the
growth factor binds specifically to the cell surface
with a dissociation constant of 5nM. There are
600-700 receptors per cell, and the cells exhibit a
half maximal response to erythropoietin at 60pM,
suggesting that as few as 10 molecules need be
bound to elicit a biological effect.
This surprisingly low number of receptors was
also found by N.A. Nicola (Walter and Eliza Hall
Institute, Melbourne Australia) for granulocyte-
colony stimulating factor (G-CSF) - a 25,000mol.wt
glycoprotein - which stimulates the proliferation of
murine granulocytic progenitor cells and the terminal
differentiation of some murine myeloid leukaemic
cells e.g. WEHI-3B D+. Both normal and myeloid
leukaemic cells have an average of -300 receptors
per cell, of mol. wt 150,000, with an apparent
dissociation constant of 70pM, whilst G-CSF is
active on WEHI - 3B D+ cells and normal granulo-
cytic precursor cells at a half maximal concentration
of 3pM.
Significantly, murine radioiodinated G-CSF binds
not only to cells of murine origin, but also to
human granulocytic cells. Ofthe two types ofhuman
colony stimulating factors (CSF-ac, CSF-f) with
some similar activities to murine G-CSF Nicola
found that human CSF-,B completely inhibits the
binding of murine G-CSF to both murine and
human cells, whilst CSF-a had no such effect. CSF-
,B and G-CSF also share all biological activities
across the two species indicating that CSF-f may
represent the human equivalent of murine G-CSF.
R. Shadduck (Monteflore Hospital, Pittsburgh
USA) has also isolated and characterized a murine
myeloid-lineage restricted growth factor known as
CSF-l or macrophage-CSF. The murine M-CSF is
a 60-70,000mol. wt dimer of which >50% is
carbohydrate. Again an ability to bind specifically
to the cell surface was demonstrated. Experiments
with radioiodinated CSF-1 showed 5000
receptors per cell, the greater number of receptors
being observed on blast and) mononuclear cells in
normal murine bone marrow. Shadduck also
described a human CSF-1 of mol.wt 60-64,000,
isolated from urine. This is also a dimer, but unlike
the G-CSF and CSF-f no cross species reactivity is
observed.
The haemopoietic growth factors described thus
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far exhibit an activity limited to a specific
haemopoietic lineage. In addition, the presence of
multipotential colony stimulating factors was
demonstrated. Murine Interleukin 3 (which is
probably the same molecular entity as haemopoietic
cell growth factor, P-cell stimulating factor, multi-
CSF and burst promoting activity) was described
by J. Ihle (National Cancer Institute, USA) as a
28,000molwt glycoprotein initially isolated by its
ability to induce the expression of the enzyme 20a
steroid dehydrogenase in stem cells. However, this
molecule has since been demonstrated to permit the
survival, proliferation and development of
progenitor cells from several distinct lineages
including erythroid, granulocyte, macrophage,
megakaryocytic and basophilic lineages and also to
allow the self-renewal and differentiation of pluri-
potential stem cell populations. Studies of Inter-
leukin 3 receptor binding to responsive cell lines
reveals that there are 1500-2500 specific receptors
per cell with a KD of 17pM. No human equivalent
which can compete with IL3 for occupation of this
receptor has yet been found, but a protein which
carries some similar properties was described by
M.A.S. Moore (Sloan-Kettering, USA). This growth
factor, named pluripoietin, has been purified to
homogeneity from the conditioned medium of a
human bladder carcinoma cell line (5637) and has a
mol. wt of 18,000. Unlike Interleukin-3 this
molecule was active across species barriers, stimu-
lating murine granulocyte/macrophage and mixed
colony formation, and stimulating the
differentiation of the murine myelomonocytic cell
line, WEHI-3BD+ (as does Nicola's G-CSF, but
not murine Interleukin-3). In addition pluripoietin
acts, like (Interleukin-3), on primitive clonogenic
progenitor cells (human CFU-GEMM) as well as
on fully differentiated cells, for example, inducing
protein synthesis in human monocytes and macro-
phages.
It was apparent from these contributions that a
complex scheme involving both lineage restricted
and multilineage haemopoietic growth factors is
emerging. In addition some of these growth factors
exhibit cross species reactivity, whilst others are
unable to do so. Another important feature of these
contributions was that the growth factors act at
very low concentrations and in addition the
receptor numbers per cell are extremely low. There
is also intriguing evidence that very few receptors
need be occupied to elicit a biological effect
suggesting that a few molecules per cell can induce
proliferation and differentiation.
Molecular cloning ofhaemopoietic growthfactors
Another route recently employed to obtain large
quantities of pure haemopoietic growth factors is
molecular cloning. A very clear account of cloning
strategies was given by Drs T. Yokota and F. Lee
(DNAX, California) who described the three
important requisities as, firstly, a source of
biologically active messenger RNA; secondly, a full
length cDNA library in a mammalian expression
vector; and thirdly reliable and sensitive biological
assays. This strategy had been employed to good
effect in their hands. to clone murine Interleukin 3
and also Interleukin 2 (T cell growth factor).
Yokota described Interleukin 3 as a polypeptide
consisting of 134 amino acid residues, mol. wt
15,000. The discrepancy between this and Ihle's
28,000mol.wt could be accounted for by the sugar
groups attached to the protein at the 4 potential N-
glycosylation sites, although the N-terminal
sequence which Ihle has reported from an amino
acid analysis of the purified protein appears to be
several residues shorter than the reported sequence
from the DNAX and Canberra groups (obtained
via molecular cloning), an anomaly which is at
present unexplained. Biological activities of Inter-
leukin 3 produced by transfected cos-7 monkey cells
were shown to include all the activities
characteristic of Interleukin 3.
A.R. Dunn (Ludwig Institutefor Cancer Research,
Melbourne) has also installed full length cDNA
fragments of not only Interleukin-3 but also
granulocyte-macrophage colony stimulating factor
(GM-CSF) into a eukaryotic expression vector and
transfected into simian cos cells where they direct
the expression of growth factors with apparently
normal biological characteristics. For the GM-CSF
molecule Dunn and co-workers (after having
obtained the cDNA sequence using a strategy
similar to that described by Yokota and Lee), have
considered the nucleotide sequence at the 5' end of
GM-CSF messenger RNA. This reveals the
presence of two AUG (initiation) codons
associated with a stable loop structure both of
which are in frame with the coding sequences of
GM-CSF. Use of these 5' AUG codons would
result in a nascent polypeptide with the
characteristics of a transmembrane protein, whereas
use of the second would result in the synthesis of a
hydrophobic leader sequence characteristic of a
secreted protein. This gives rise to the intriguing
speculation that GM-CSF may, in some cases, exist
as a membrane bound protein which can present
itself to neighbouring cells only. This may .have
important implications for the role of the stromal
microenvironment in supporting haemopoiesis in
that expression of growth factor activity at the
membrane may play a key role in the cell:cell
interactions, known to be of fundamental
importance in haemopoiesis.
Using the sequences derived for GM-CSF and
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both the DNAX and Melbourne groups) to identify
a human counterpart to these murine molecules.
However, both these groups have had little success
in obtaining a human equivalent to Interleukin-3.
On the other hand Lee (of DNAX) did report the
identification of a human equivalent to murine
GM-CSF whose biological activities were in the
process of being tested.
Several important points arose from the work
described by the molecular biologists. Firstly the
molecular cloning of haemopoietic growth factors is
possible and expression of biologically active growth
factors can be achieved in both prokaryotic and
eukaryotic systems. Second, it is apparent that the
high degree of glycosylation found on many of
these haemopoietic growth factors is not necessary
for biological activity (this was reported by A.D.
Whetton (Paterson Laboratories, Manchester), who
said that studies by L. Healey and G. W. Bazill
(Paterson Laboratories, Manchester) had shown that
highly purified Interleukin 3, isolated from WEHI-
3B cell conditioned medium, retained full biological
activity when stripped of its carbohydrate groups
with endoglycosidase F). Third, although some
growth factors exhibit some species conservation
this is not always the case. Fourth, production of
large amounts of molecularly cloned material is at
the moment presenting something of a problem. No
effective procedure has yet been found to yield
large amounts of biologically active protein from
transfected eukaryotic or prokaryotic cells. Fifth,
the structure and expression of the growth factor
genes and the possible form the protein can take
(i.e. membrane bound or soluble) can now be
explored much more readily with the sequence data
obtained by molecular biological techniques.
Biological activities ofhaemopoietic growthfactors
The range of activities and specificities of haemo-
poietic growth factors has been described to some
extent but obviously many questions still remain. In
particular how do all the regulatory molecules act
together in vivo to maintain haemopoietic homeo-
stasis and what are the events leading to disruption
of haemopoiesis? Oncogenes have been implicated
in growth regulation in many systems and their
influence on the production of, and response to,
haemopoietic growth factors is being investigated.
As in the murine and human systems, haemo-
poietic growth factors have been isolated from
chickens. A. Leutz (EMBL, Heidelberg) described
the purification of chicken myelomonocytic growth
factor (cMGF), which has the ability to promote
macrophage colony development from normal
chicken bone marrow. This factor was also able to
promote survival of cMGF-dependent chicken
myeloblast cell lines that are produced following
transformation by retroviruses encoding the v-myb
and v-myc oncogenes. However, macrophages
transformed by the MHZ virus were independent of
cMGF for survival; the MHZ virus encodes both v-
myc and the src-related v-mil. Leutz subsequently
showed that the cMGF-dependent v-myb trans-
formed myeloblasts could be rendered factor-
independent by other src-related retroviral
sequences (e.g. v-fps, v-yes, v-ros) but not by v-myc.
Similarly, v-src converted the factor-dependent v-
myb transformed cells to independence, but not the
v-myc transformed myeloblasts. The conversion to
factor-independence is associated with the
production of a cMGF-like substance by the cells,
indicating the the survival of the cells requires
autocrine stimulation. Experiments along similar
lines, with mouse cell lines, were described by IhIe.
In this case IL3-dependent cell lines were infected
with molecular recombinants containing v-myc
from MHZ or MC-29 viruses, resulting in factor-
independence of the cell lines. In further contrast to
Leutz's results these factor-independent cells
retained the receptors for IL3 but did not
themselves produce it, nor did antiserum to IL3
block the growth of the cells. This suggests that the
requirement for normal growth factor had been
bypassed in some way.
Another approach to investigating the possible
role of oncogenes in the control of haemopoiesis
was discussed by E. Spooncer (Paterson
Laboratories, Manchester). Long-term bone marrow
cultures were infected with virus containing the src
oncogene which resulted in long-term and stable
changes in the haemopoietic activity in the cultures,
viz. an almost complete block in the output of
mature cell types and a build up of primitive cell
types. This was accompanied by the expression of
apparently unlimited self-renewal capacity by the
haemopoietic stem cells. Furthermore, it was
possible to derive cell lines from these cultures
which were dependent on IL3 for their survival,
were non-leukaemic and possessed many of the
characteristics of the stem cell. The role of the
oncogene in the transformation of haemopoietic
activity following infection with src is not quite
clear. Due to the failure to detect the src kinase
activity specifically associated with cells of haemo-
poietic origin there is a possibility that these effects
may have been mediated via a direct influence of
the src oncogene on stromal cells of the haemo-
poietic environment, which subsequently resulted in
a modification of haemopoietic activity. These
studies showed diverse influences of v-oncogenes on
haemopoiesis in promoting the emergence of factor-
dependent cell lines; factor-independent cell lines
which appear either to produce their own supply of
IL3 or to be totally autonomous of normal growth
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stem cells. This raises the question of whether
analogous c-oncogenes are, in fact, involved in the
control of normal haemopoietic cell development in
response to growth factors.
Some progress has recently been made in
describing, in biochemical terms, the nature of
dependence of haemopoietic cells on IL3. Whetton
demonstrated a chain of biochemical events which
IL3-dependent cell lines undergo in response to
IL3, but not in response to any other, non-specific,
growth factors. In the presence of IL3, intracellular
ATP levels are maintained in the cells. In its
absence ATP levels rapidly fall. In fact limited
survival of the cells could be effected by an ATP-
regenerating system in the absence of IL3. The IL3
was shown to be acting on the ATP-generating
machinery of the cell at the level of glycolysis and
the point of regulation of this process is the
transport of glucose into the cell by the glucose
transport protein. Presumably the binding of IL3 to
its receptor activates (directly or indirectly) the
glucose transport mechanism and the subsequent
production of ATP by glycolysis ensures survival of
the cell. The requirement for some step in this
chain of events is clearly bypassed in the case of the
factor-independent cell lines described by Ihle and
such cell lines should permit determination of the
biochemical changes that lead to the emergence of
autonomous haemopoietic cells.
In most studies of the action of growth factors
the factors are produced in vitro from cell lines
or normal tissues stimulated in some way. The in
vivo function of the molecules and their source and
presentation to target cells is poorly understood.
Various suggestions indicate the production of
growth factors by adherent (stromal) cells and
accessory cells to the target cells. J. W. Adamson
(University ofWashington, USA) described a response
ofhaemopoietic cells to PDGF, which was mediated
by interaction of stromal cells with PDGF and a
modulation of growth factor production from
stromal cells (endothelial cells and fibroblasts) by
other cell types, in this case, monocytes C.J. Paige
(Basel Institute for Immunology, Switzerland) has
developed a colony forming cell assay for B-cell
progenitors which is dependent upon factors
produced by accessory cells contained in the
adherent foetal liver cell population. In fact IL3,
M-CSF and GM-CSF have the capacity to promote
the production of the factor required for
development of the B-cell colonies from the
accessory cell type. It is clearly more of a problem to
perform studies on the in vivo relevance of growth
factors in humans than mice. However, H. Messner
(Ontario Cancer Institute, Toronto, Canada) has
detected growth factors in platelet-free human
plasma samples and in particular has correlated a
prolonged presence of megakaryocyte-colony
stimulating activity with a delayed return of
platelets in patients following bone marrow trans-
plantation.
H. Broxmeyer (Indiana University, USA) dis-
cussed a molecule termed leukaemia associated in-
hibitory activity which, by some criteria, may be
classed as a member of the acidic isoferritin family.
This molecule has the capacity to suppress colony
formation by Ia' GM-CFC, BFU-E and MxCFC
which are in cell cycle and from normal donors but
not from leukaemic human donors. There is some
difficulty, however, in fitting in a molecule with the
characteristics described by Broxmeyer in any of
the known categories of ferritins. The main
objections, from A. Jacobs (Welsh National School
of Medicine, Cardiff, UK) were the facts that the
active concentration of this molecule on haemo-
poietic cells (10-18 M) is less than the plasma
concentration of ferritin, that considerably more
than this should be produced by the culture itself,
and that a glysoylated acidic isoferrin (as described
by Broxmeyer) has not previously been identified.
According to Jacobs only serum ferritins are
glycosylated and these molecules are not acidic in
nature. Joint experiments between these groups so
far yielded only variable and inconsistent results.
Definite proof of the putative identify of the
molecule which can suppress colony formation with
acidic isoferritin appears to await assay of material
expressed by the families of genes coding for sub-
units of acid isoferritins.
On a more general aspect of growth factors M.F.
Greaves (Leukaemic Research Fund, London, UK)
described the structure and role of the transferrin
receptor. In discussions he clearly pointed out that
it was important to be aware of the difference
between more general growth factors, such as
transferrin and its receptor which appear to
function for all cell types, and lineage restricted
specific growth factors which, in general, have been
the subjects of this symposium. The transferrin
receptor is present on all dividing cells, is increased
in cycling cells and absent on quiescent cells. The
transferrin receptor may also be involved in
differentiation. Greaves discussed the possibility
that NK cells may recognise the transferrin receptor
and function as a cellular mechanism for down-
grading the rate of growth. The fact that the
expression of the transferrin receptor is ubiquitous
on dividing cells, but the cellular targets for NK
cells are more restricted suggests that this
speculation must be somewhat refined in order to
explain such a role for the transferrin receptor.
Overall, this symposium covered a wide range of
aspects involved with the role of growth factors in
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been achieved since the 15th Paterson symposium
on analysis of haemopoietic stem cell behaviour in
1980. Predictably, the advances have been parti-
cularly associated with use of recently developed
techniques in molecular biology and clearly cell
biologists and biochemists must now finish off
defining the role of the growth factors, which will
probably soon be available in a pure form and in
large quantities. However, the step from in vitro
studies to understanding the in vivo control of
haemopoiesis still poses a big challenge.
The symposium was organised by BI. Lord (Paterson
Laboratories, Manchester), who assembled an excellent
group of international scientists in this field, ensuring that
discussion was lively and valuable. The Paterson
Laboratories would like to acknowledge the sponsorship
of the Cancer Research Campaign, UK, Searle Research
and Development and ICI Pharmaceuticals Division. The
CRC generously provided a grant for the travel of three
overseas participants, Searle Research another and in a
scheme to encourage the development of young scientists
the CRC also sponsored the participation of two post-
graduate students.